The Impact of Chronic Urticaria from the Patient's Perspective: A Survey in Five European Countries.
The Impact of Chronic Urticaria from the Patient's Perspective: A Survey in Five European Countries.
复制标题
DOI：
10.1007/s40271-015-0145-9
复制
发表时间：
2015-12
期刊：
影响因子：
--
通讯作者：
Isherwood G
中科院分区：
文献类型：
--
作者：
Balp MM;Vietri J;Tian H;Isherwood G
慢性自发性荨麻疹（CSU）与相当大的负担，但数据来自欧洲患者是有限的。这项研究是对2010年至2013年期间收集的五个最大的欧盟国家（5EU：法国，德国，意大利，西班牙和英国）的国家健康和健康调查数据的回顾性横断面分析。通过比较目前接受慢性荨麻疹治疗的个体（代理CSU病例）与从无慢性荨麻疹的应答者中选择的对照组，估计CSU患者的疾病负担。匹配和回归模型被用来量化慢性荨麻疹对健康相关的生活质量，自我报告的心理投诉，工作和活动障碍，以及医疗保健使用的影响。样本包括175，923名受访者。诊断的慢性荨麻疹患病率为0.5，0.2%的人用处方治疗。病例（N = 369）的回归校正平均心理健康评分显著较低（较差）（40.2 vs. 45.4），物理组件总结（44.6 vs. 49.9）和SF-6D健康效用评分（0.63 vs. 0.71;所有p < 0.001）相对于对照组（N = 1476），差异超过了这些测量的可接受的最小重要差异。抑郁、焦虑和睡眠困难在目前接受慢性荨麻疹治疗的患者中的患病率约为2倍（所有p < 0.001）。与对照组相比，病例还具有较高的出勤率（31 vs. 17%），总体工作障碍（37 vs. 20%）和非工作活动障碍（42 vs. 26%;所有p < 0.01）。医生就诊（9.1 vs. 4.9）、急诊室就诊（0.8 vs. 0.3）和住院（0.3 vs. 0.2）比对照组更频繁（均p < 0.01）。这项研究增加了现有的证据表明CSU的重大负担。本文的在线版本（doi：10.1007/s40271-015-0145-9）包含补充材料，可供授权用户使用。
Chronic spontaneous urticaria (CSU) is associated with considerable burden, but data from European patients are limited. This study is a retrospective, cross-sectional analysis of National Health and Wellness Survey data from the five largest EU countries (5EU: France, Germany, Italy, Spain, and the UK) collected between 2010 and 2013. Burden of disease for patients with CSU was estimated by comparing individuals currently treated for chronic urticaria (proxy CSU cases) with controls selected from respondents without chronic urticaria. Matching and regression models were used to quantify the impact of chronic urticaria on health-related quality of life, self-reported psychological complaints, work and activity impairment, and healthcare use. The sample included 175,923 respondents. Prevalence of diagnosed chronic urticaria was 0.5 and 0.2 % were treating the condition with a prescription. Cases (N = 369) had substantially lower (worse) regression-adjusted mean Mental Component Summary (40.2 vs. 45.4), Physical Component Summary (44.6 vs. 49.9), and SF-6D health utility scores (0.63 vs. 0.71; all p < 0.001) relative to controls (N = 1476), differences that exceed accepted minimally important differences for these measures. Depression, anxiety, and sleep difficulties were approximately twice as prevalent among those currently receiving treatment for chronic urticaria (all p < 0.001). Cases also had elevated presenteeism (31 vs. 17 %), overall work impairment (37 vs. 20 %), and impairment in non-work activities (42 vs. 26 %; all p < 0.01) relative to controls. Physician visits (9.1 vs. 4.9), emergency room visits (0.8 vs. 0.3), and hospitalizations (0.3 vs. 0.2) were more frequent than in controls (all p < 0.01). This research adds to the existing evidence showing significant burden of CSU. The online version of this article (doi:10.1007/s40271-015-0145-9) contains supplementary material, which is available to authorized users.